News
Our in person events and activities have been on hold since March. We're taking a phased approach to starting them back up.
Simvastatin is a drug already used to lower cholesterol, and prevent heart attacks and strokes. Initial results from a major clinical trial show it doesn't have potential to slow the progression of Parkinson's as previously hoped.
Researchers in Portugal have discovered that the content of dreams, particularly those with negative emotions, may predict long-term cognitive decline in people with Parkinson’s.
An international team of researchers have uncovered a biological link that may account for why those with diabetes have a higher risk of developing Parkinson’s.
We’re investing a further £1 million to drive forward drugs that target energy-producing mitochondria to slow the loss of brain cells in Parkinson's.
Parkinson's UK has invested an additional £1 million in NRG Therapeutics Ltd’s mitochondrial drug development programme.
With Lancaster University, we conducted a survey that shows the coronavirus restrictions are having a big impact on the lives and the health of people affected by Parkinson’s.
Parkinson’s UK chose to stay quiet during the recent Black Lives Matter conversations. We believed that by giving others space to have their voices heard, we were playing a role in supporting their message. We were wrong.
A team of researchers at the University of York have shown a protein called Rab10 plays an important role in the loss of brain cells in LRRK2-associated Parkinson’s.
Cannabis-based compounds could be the silver bullet to relieve pain for people with Parkinson’s according to the largest ever study into pain and the condition.